
Ankylosing spondylitis Program in Pharmaceutical Benefits Scheme (PBS) 012-18051102

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the PBS-subsidised biological agents
for patients with ankylosing spondylitis (AS).

Ankylosing spondylitis and listing dates

Ankylosing spondylitis (AS) is an inflammatory disease of the joints in
the spine.

Listing dates are:

-   infliximab - 1 August 2004
-   etanercept - 1 April 2005
-   adalimumab - 1 March 2007
-   golimumab - 1 August 2010
-   certolizumab pegol - 1 September 2014
-   secukinumab - 1 October 2016
-   ixekizumab - 1 December 2020
-   upadacitinib - 1 October 2021

For more information, see Written Authority Required Drugs.

Note: as of 1 October 2021, there has been a cycle reset for this
program. This means that all previous trials and failures of
PBS-subsidised biological medicines for a patient for this condition
have been reset.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, calculation
sheets, contact details, item and restriction codes, FAQs, the PBS
schedule and the Services Australia website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing written authority approval requests

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
